KIRAN MAZUMDAR-SHAW
Founded Biocon, India's largest biopharmaceutical company, and became one of the most influential women in global business.
Kiran Mazumdar-Shaw started Biocon in a garage in Bangalore in 1978 with $200 in seed capital. Indian banks refused to lend to a 25-year-old woman starting a biotech company. Forty-six years later, Biocon is worth over $5 billion, makes biosimilar drugs that cost a fraction of Western originals, and supplies affordable cancer and diabetes treatments to 120+ countries. She proved that you can build a world-class pharmaceutical company in India — you just have to ignore everyone who says you cannot.
Net Worth
$3.5 billion
Nationality
Indian
Time Horizon
Generational
Risk Appetite
7 / 10
CAREER & BACKGROUND
Born in 1953 in Bangalore. Her father was the head brewmaster at United Breweries.
She studied zoology at Bangalore University, then earned a master's in malting and brewing from the University of Ballarat in Australia — she wanted to follow her father into brewing. But no Indian brewery would hire a woman in the 1970s.
Frustrated, she partnered with Irish biotech company Biocon Biochemicals to start a subsidiary in India. She founded Biocon India in 1978 in her garage with just $200 and two employees.
The company initially produced enzymes for brewing and textiles, then pivoted to pharmaceuticals in the 1990s.
Biocon went public on the BSE in 2004 — making Mazumdar-Shaw India's richest self-made woman. The company pioneered biosimilars — biologically similar versions of expensive drugs that cost a fraction of the originals.
Biocon's insulin products serve millions of diabetics across developing nations. By 2024, Biocon was valued at over $5 billion with operations in 120+ countries.
COMPANIES & ROLES
Founder and Executive Chairperson of Biocon (1978-present). Biocon is India's largest biopharmaceutical company.
Pioneer of affordable biosimilar drugs. Biocon IPO'd in 2004.
Serves 120+ countries. Also founded Biocon Foundation (healthcare access for the poor).
Member of numerous global boards including MIT Corporation.
INVESTING STYLE & PHILOSOPHY
Long-term, mission-driven building. Mazumdar-Shaw has spent 46 years building one company.
She is not a speculative investor or a serial entrepreneur. Her approach is patient capital applied to a massive social problem — making drugs affordable for the developing world.
THE PLAYBOOK
Risk Approach
High but calculated. Starting a biotech company in India in 1978 was an enormous risk — there was no biotech ecosystem, no venture funding, and systemic bias against women entrepreneurs.
But Mazumdar-Shaw took measured steps, building revenue from enzymes before pivoting to more ambitious pharmaceutical products.
Money Habits
Lives in Bangalore. Known for her philanthropy — the Biocon Foundation provides free healthcare to rural Indians.
Not flashy by billionaire standards. Drives herself to work.
Deeply connected to Bangalore's civic and tech communities. She is one of the most vocal advocates for women in Indian business.
BIGGEST WIN
Biocon's biosimilar insulin. The company makes insulin that costs a fraction of Western pharmaceutical prices, making diabetes treatment accessible to millions of patients who could never afford the original branded versions.
This is not just a business win — it has materially improved health outcomes across the developing world.
BIGGEST MISTAKE
The US market has been harder to crack than expected. Biocon has faced regulatory hurdles getting biosimilar approvals from the FDA, and the US pharmaceutical industry's resistance to lower-cost alternatives has slowed growth in the most profitable market in the world.
FINANCIAL PHILOSOPHY
Making expensive things affordable is the greatest business opportunity in the world. Mazumdar-Shaw has built Biocon around the thesis that billions of people need medicines they cannot afford.
If you can make those drugs at a fraction of the cost with equivalent quality, you have an unlimited market.
FAMILY & PERSONAL LIFE
Married to John Shaw, a Scottish-born businessman who serves as Biocon's vice chairman. The couple does not have children.
Her father's career in brewing directly shaped her educational path and eventually her career in biotechnology.
EDUCATION
Bangalore University (BSc in Zoology). University of Ballarat, Australia (Master's in Malting and Brewing Science).
Her brewing science background was the foundation for understanding fermentation — which is central to biotech manufacturing.
BOOKS & RESOURCES
Mazumdar-Shaw has cited its message of using crises to build a better world
The women's leadership framework
My Experiments with Truth by Mahatma Gandhi
The autobiography that influenced her values-driven business approach
As an Amazon Associate, Netfigo earns from qualifying purchases. Book links above may be affiliate links.
QUOTES (5)
I wanted to be a brewmaster like my father. No brewery in India would hire a woman. Biotechnology was my second choice — and my best decision.
Biocon's insulin serves millions of diabetics who could never afford the branded version. That is what keeps me going after 46 years.
India can be the pharmacy of the world. We have the talent, the scale, and the cost advantage. We just need the ambition.
Banks wouldn't lend to a 25-year-old woman starting a biotech company in 1978. So I started with $200 in my garage.
Making expensive drugs affordable is not charity. It is the biggest business opportunity in the world.
NETFIGO SCORE
Proprietary 5-dimension investor rating
Risk Appetite
Contrarian Index
Track Record
Accessibility
Time Horizon
Related Profiles
Head-to-Head
Compare Kiran Mazumdar-Shaw vs another investor.